Celosia Therapeutics is an innovative biotech startup dedicated to developing cutting-edge genetic medicines for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS) and Dementia (Alzheimer’s & FTD). Our mission is to provide transformative treatment options to patients with limited therapeutic alternatives.

Why work with us

Celosia Therapeutics is advancing a first-in-class gene therapy for ALS, specifically targeting TDP-43 pathology.

With funds from our recent Series A raise, we've successfully completed our pre-clinical development program and are firmly on track to initiate clinical trials in Q3, 2025.

Given our strong clinical momentum and the significant support we've secured from investors, we believe there’s a compelling opportunity to collaborate as we progress towards the clinic.